Cogent Biosciences Submits NDA for Bezuclastinib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- NDA Submission: Cogent Biosciences has submitted a New Drug Application (NDA) to the U.S. FDA for Bezuclastinib, aimed at treating advanced systemic mastocytosis, marking a significant advancement in the biotechnology sector.
- Clinical Trial Support: The NDA is backed by positive data from the pivotal Phase 3 APEX trial involving 81 patients, demonstrating at least a 50% reduction in bone marrow mast cell concentration, with 89% of patients achieving normalization of serum tryptase levels.
- Significant Efficacy: The overall response rate in treated patients reached 81%, with 12-month data indicating a 79% progression-free survival rate and an 87% overall survival rate, showcasing Bezuclastinib's potential in treatment.
- Market Performance: Although Cogent Biosciences is currently trading at $38.38, down 0.83%, the NDA submission could positively influence the company's future market performance, particularly enhancing its competitiveness in the rare disease sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COGT
Wall Street analysts forecast COGT stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 39.440
Low
34.00
Averages
50.36
High
67.00
Current: 39.440
Low
34.00
Averages
50.36
High
67.00
About COGT
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cogent Biosciences Submits NDA for Bezuclastinib
- NDA Submission: Cogent Biosciences has submitted a New Drug Application (NDA) to the U.S. FDA for Bezuclastinib, aimed at treating advanced systemic mastocytosis, marking a significant advancement in the biotechnology sector.
- Clinical Trial Support: The NDA is backed by positive data from the pivotal Phase 3 APEX trial involving 81 patients, demonstrating at least a 50% reduction in bone marrow mast cell concentration, with 89% of patients achieving normalization of serum tryptase levels.
- Significant Efficacy: The overall response rate in treated patients reached 81%, with 12-month data indicating a 79% progression-free survival rate and an 87% overall survival rate, showcasing Bezuclastinib's potential in treatment.
- Market Performance: Although Cogent Biosciences is currently trading at $38.38, down 0.83%, the NDA submission could positively influence the company's future market performance, particularly enhancing its competitiveness in the rare disease sector.
See More
Cogent Biosciences Presents New Data on JAK2 Inhibitor
- Preclinical Data Presentation: Cogent Biosciences showcased preclinical data for its JAK2 V617F mutant-selective inhibitor CGT1145 at the 2026 European Hematology Association Congress, indicating its potential best-in-class properties in selectivity and potency, which could significantly enhance patient treatment outcomes.
- IND Application Progress: The company is on track to submit an Investigational New Drug application for CGT1145 in 2026, marking a rapid advancement in developing precision therapies for BCR-ABL-negative myeloproliferative neoplasms, potentially offering new treatment options for patients.
- Selectivity Advantage: CGT1145 exhibits over 100-fold selectivity for the JAK2 V617F mutation compared to JAK2 WT and JAK1/3 isoforms, demonstrating its potential to reduce off-target effects, which will help improve patient tolerability and quality of life.
- Market Potential: Given the high prevalence of the JAK2 V617F mutation in myeloproliferative neoplasm patients (e.g., 95% of polycythemia vera patients), the successful development of CGT1145 could position it prominently in the market to meet unmet medical needs.
See More
Cogent Biosciences Reports PEAK Trial Results
- Clinical Trial Results: Cogent Biosciences presented detailed Phase 3 results from the PEAK trial at the 2026 ASCO annual meeting, demonstrating that Bezuclastinib in combination with Sunitinib offers a statistically significant survival advantage in patients with gastrointestinal stromal tumors previously treated with Imatinib, with a median PFS of 16.5 months compared to 9.2 months with Sunitinib alone, yielding a hazard ratio of 0.50 and a p-value of 0.0001.
- Treatment Duration: The average treatment duration extended to 21.4 months, indicating that patients receiving the Bezuclastinib and Sunitinib combination can achieve a longer progression-free survival, thereby enhancing the clinical significance of this therapy.
- Safety Assessment: Safety findings indicate that the regimen was well tolerated, with no new risks beyond the known profile of Sunitinib, and patients experienced manageable side effects without unique toxicities, suggesting a balance of safety and efficacy for this treatment approach.
- FDA Review Progress: The FDA has accepted Cogent's NDA for the Bezuclastinib combination and granted Priority Review, with a PDUFA date set for November 30, 2026, highlighting the potential market prospects for this drug.
See More
Bezuclastinib Combination Shows Significant Benefit in GIST Patients
- Clinical Trial Results: The combination of Bezuclastinib and sunitinib demonstrated a significant progression-free survival (PFS) advantage in GIST patients, achieving 16.5 months compared to 9.2 months for sunitinib alone, with a hazard ratio of 0.50 (p<0.0001), marking a major breakthrough in treatment efficacy.
- Good Tolerability: The combination therapy was well tolerated, consistent with the known safety profile of sunitinib, and no unique risks were observed, indicating its potential for clinical application and the possibility of becoming a new standard of care.
- FDA Priority Review: The FDA has accepted the NDA for the Bezuclastinib combination and granted priority review, with a PDUFA date set for November 30, 2026, providing new hope for patients in need of effective treatment options.
- New Clinical Trial Initiation: Cogent announced the initiation of a new clinical trial to evaluate the safety and efficacy of the Bezuclastinib combination in first-line GIST patients, further validating its application potential across different patient populations.
See More
Cogent Biosciences Set for Dual Product Launches
- FDA Priority Review: Cogent Biosciences' lead candidate, bezuclastinib, has received FDA priority review for its New Drug Application targeting gastrointestinal stromal tumors (GIST), with a target action date set for November 30, 2026, which could provide a new treatment option for patients.
- Combination Therapy: The drug is intended for use in combination with Pfizer's GIST therapy, sunitinib, specifically for patients who have previously been treated with imatinib, aiming to enhance treatment efficacy and meet the urgent market demand for new therapies.
- Significant Market Potential: CEO Andrew Robbins expressed excitement over the acceptance of the bezuclastinib NDA for GIST, indicating that preparations for the expected launches in both GIST and systemic mastocytosis are well underway, reflecting the company's confidence in the market potential of the new drug.
- Dual Launch Strategy: In addition to GIST, the NDA for bezuclastinib targeting non-advanced systemic mastocytosis has also been accepted by the FDA, with a target action date of December 30, 2026, further enhancing Cogent Biosciences' competitive position in the market.
See More
FDA Accepts Bezuclastinib NDA with Priority Review
- NDA Approval: Cogent Biosciences' New Drug Application for Bezuclastinib in combination with Sunitinib has been accepted by the FDA for Priority Review, with a PDUFA date set for November 30, 2026, marking a significant advancement in GIST treatment and potentially enhancing market competitiveness.
- Clinical Trial Results: The PEAK Phase 3 trial demonstrated a median progression-free survival of 16.5 months for the Bezuclastinib combination compared to 9.2 months for Sunitinib monotherapy, indicating a 50% reduction in risk (HR=0.50), which provides a new treatment option for GIST patients and may redefine treatment standards.
- Safety Data: The safety profile of the Bezuclastinib combination was comparable to Sunitinib, with common adverse events including hypertension and neutropenia, and most adverse reactions were manageable low-grade events, ensuring patient acceptance and treatment continuity.
- ASCO Presentation: Cogent plans to present the full results of the PEAK trial at the ASCO conference on May 30, 2026, further enhancing the company's visibility in the biopharmaceutical sector and preparing for the upcoming market launch.
See More
Cogent Biosciences Submits NDA for Bezuclastinib
- NDA Submission: Cogent Biosciences has submitted a New Drug Application (NDA) to the U.S. FDA for Bezuclastinib, aimed at treating advanced systemic mastocytosis, marking a significant advancement in the biotechnology sector.
- Clinical Trial Support: The NDA is backed by positive data from the pivotal Phase 3 APEX trial involving 81 patients, demonstrating at least a 50% reduction in bone marrow mast cell concentration, with 89% of patients achieving normalization of serum tryptase levels.
- Significant Efficacy: The overall response rate in treated patients reached 81%, with 12-month data indicating a 79% progression-free survival rate and an 87% overall survival rate, showcasing Bezuclastinib's potential in treatment.
- Market Performance: Although Cogent Biosciences is currently trading at $38.38, down 0.83%, the NDA submission could positively influence the company's future market performance, particularly enhancing its competitiveness in the rare disease sector.
See More
Cogent Biosciences Presents New Data on JAK2 Inhibitor
- Preclinical Data Presentation: Cogent Biosciences showcased preclinical data for its JAK2 V617F mutant-selective inhibitor CGT1145 at the 2026 European Hematology Association Congress, indicating its potential best-in-class properties in selectivity and potency, which could significantly enhance patient treatment outcomes.
- IND Application Progress: The company is on track to submit an Investigational New Drug application for CGT1145 in 2026, marking a rapid advancement in developing precision therapies for BCR-ABL-negative myeloproliferative neoplasms, potentially offering new treatment options for patients.
- Selectivity Advantage: CGT1145 exhibits over 100-fold selectivity for the JAK2 V617F mutation compared to JAK2 WT and JAK1/3 isoforms, demonstrating its potential to reduce off-target effects, which will help improve patient tolerability and quality of life.
- Market Potential: Given the high prevalence of the JAK2 V617F mutation in myeloproliferative neoplasm patients (e.g., 95% of polycythemia vera patients), the successful development of CGT1145 could position it prominently in the market to meet unmet medical needs.
See More
Cogent Biosciences Reports PEAK Trial Results
- Clinical Trial Results: Cogent Biosciences presented detailed Phase 3 results from the PEAK trial at the 2026 ASCO annual meeting, demonstrating that Bezuclastinib in combination with Sunitinib offers a statistically significant survival advantage in patients with gastrointestinal stromal tumors previously treated with Imatinib, with a median PFS of 16.5 months compared to 9.2 months with Sunitinib alone, yielding a hazard ratio of 0.50 and a p-value of 0.0001.
- Treatment Duration: The average treatment duration extended to 21.4 months, indicating that patients receiving the Bezuclastinib and Sunitinib combination can achieve a longer progression-free survival, thereby enhancing the clinical significance of this therapy.
- Safety Assessment: Safety findings indicate that the regimen was well tolerated, with no new risks beyond the known profile of Sunitinib, and patients experienced manageable side effects without unique toxicities, suggesting a balance of safety and efficacy for this treatment approach.
- FDA Review Progress: The FDA has accepted Cogent's NDA for the Bezuclastinib combination and granted Priority Review, with a PDUFA date set for November 30, 2026, highlighting the potential market prospects for this drug.
See More
Bezuclastinib Combination Shows Significant Benefit in GIST Patients
- Clinical Trial Results: The combination of Bezuclastinib and sunitinib demonstrated a significant progression-free survival (PFS) advantage in GIST patients, achieving 16.5 months compared to 9.2 months for sunitinib alone, with a hazard ratio of 0.50 (p<0.0001), marking a major breakthrough in treatment efficacy.
- Good Tolerability: The combination therapy was well tolerated, consistent with the known safety profile of sunitinib, and no unique risks were observed, indicating its potential for clinical application and the possibility of becoming a new standard of care.
- FDA Priority Review: The FDA has accepted the NDA for the Bezuclastinib combination and granted priority review, with a PDUFA date set for November 30, 2026, providing new hope for patients in need of effective treatment options.
- New Clinical Trial Initiation: Cogent announced the initiation of a new clinical trial to evaluate the safety and efficacy of the Bezuclastinib combination in first-line GIST patients, further validating its application potential across different patient populations.
See More
Cogent Biosciences Set for Dual Product Launches
- FDA Priority Review: Cogent Biosciences' lead candidate, bezuclastinib, has received FDA priority review for its New Drug Application targeting gastrointestinal stromal tumors (GIST), with a target action date set for November 30, 2026, which could provide a new treatment option for patients.
- Combination Therapy: The drug is intended for use in combination with Pfizer's GIST therapy, sunitinib, specifically for patients who have previously been treated with imatinib, aiming to enhance treatment efficacy and meet the urgent market demand for new therapies.
- Significant Market Potential: CEO Andrew Robbins expressed excitement over the acceptance of the bezuclastinib NDA for GIST, indicating that preparations for the expected launches in both GIST and systemic mastocytosis are well underway, reflecting the company's confidence in the market potential of the new drug.
- Dual Launch Strategy: In addition to GIST, the NDA for bezuclastinib targeting non-advanced systemic mastocytosis has also been accepted by the FDA, with a target action date of December 30, 2026, further enhancing Cogent Biosciences' competitive position in the market.
See More
FDA Accepts Bezuclastinib NDA with Priority Review
- NDA Approval: Cogent Biosciences' New Drug Application for Bezuclastinib in combination with Sunitinib has been accepted by the FDA for Priority Review, with a PDUFA date set for November 30, 2026, marking a significant advancement in GIST treatment and potentially enhancing market competitiveness.
- Clinical Trial Results: The PEAK Phase 3 trial demonstrated a median progression-free survival of 16.5 months for the Bezuclastinib combination compared to 9.2 months for Sunitinib monotherapy, indicating a 50% reduction in risk (HR=0.50), which provides a new treatment option for GIST patients and may redefine treatment standards.
- Safety Data: The safety profile of the Bezuclastinib combination was comparable to Sunitinib, with common adverse events including hypertension and neutropenia, and most adverse reactions were manageable low-grade events, ensuring patient acceptance and treatment continuity.
- ASCO Presentation: Cogent plans to present the full results of the PEAK trial at the ASCO conference on May 30, 2026, further enhancing the company's visibility in the biopharmaceutical sector and preparing for the upcoming market launch.
See More
